Lincomycin HCl Injection

Active Ingredients: Lincomycin HCl

Lincomycin HCl Injection is a parenteral lincosamide antibacterial medicine formulated for human use at a strength of 600mg/2ml (300mg/ml). It is used for serious infections caused by susceptible strains of streptococci, pneumococci and staphylococci. Its use is generally reserved for patients with a penicillin allergy or for situations in which, in the judgment of the prescribing clinician, a penicillin is inappropriate.

Selection of lincomycin should be guided by the locally approved prescribing information, the site and severity of infection, and culture and susceptibility results when available. The U.S. FDA provides current [antibacterial susceptibility testing criteria](https://www.fda.gov/STIC) to support evidence-based interpretation of antimicrobial susceptibility results.

Lincomycin inhibits bacterial protein synthesis by binding to the 23S RNA of the 50S ribosomal subunit. It is predominantly bacteriostatic in vitro. Cross-resistance can occur between lincomycin and clindamycin, and resistance patterns should be considered when selecting therapy.

Lincomycin should not be used for viral infections or minor bacterial infections for which safer antimicrobial options are appropriate. It is also not recommended for the treatment of meningitis because concentrations achieved in cerebrospinal fluid may be inadequate.

AdvaCare Pharma manufactures Lincomycin HCl Injection as a sterile small-volume human pharmaceutical injection for international markets. The 600mg/2ml presentation is available in ampoule packaging for professional healthcare use, with packaging and regulatory documentation supplied according to applicable market requirements.

This page describes Lincomycin HCl Injection for human pharmaceutical use. For animal-health applications, see the separate [Veterinary Lincomycin HCl Injection](https://www.advacarepharma.com/en/veterinary/lincomycin-hcl-injection).

AdvaCare Pharma is a leading manufacturer of Lincomycin Injection. To ensure the quality of our manufactured pharmaceutical injection products, we adhere to stringent GMP guidelines at our manufacturing facilities. We partner with pharmaceutical distributors, hospitals, pharmacies, NGOs, and government institutions across over 65 markets worldwide, and our track record over the past two decades demonstrates that AdvaCare Pharma is a reliable Lincomycin manufacturer and supplier dedicated to high-quality and efficacious medicines.

What is Lincomycin HCl used for?

Lincomycin HCl Injection is used for serious bacterial infections caused by susceptible strains of streptococci, pneumococci, and staphylococci. Its use is generally reserved for patients with a penicillin allergy or when a penicillin is considered inappropriate by the prescribing clinician.

Lincomycin should not be used for minor bacterial infections or viral infections. When culture and susceptibility results are available, they should be considered when selecting or modifying antibacterial therapy.

How is a Lincomycin HCl Injection used?

This medication is manufactured as a solution for parenteral administration. It may be administered by intramuscular (IM) injection or by intravenous (IV) infusion under the supervision of a qualified healthcare professional.

For IV administration, lincomycin must be diluted in a suitable infusion solution and administered slowly. It should not be given as a rapid IV bolus.

How does Lincomycin HCl Injection work?

Lincomycin binds to the 23S RNA of the 50S bacterial ribosomal subunit and inhibits protein synthesis. Its activity is predominantly bacteriostatic, meaning it inhibits the growth and multiplication of susceptible bacteria.

Cross-resistance can occur between lincomycin and clindamycin. Local susceptibility patterns and microbiology results should therefore be considered when treatment is selected.

What dose should be given?

The dose and duration of treatment depend on the severity and site of infection, the susceptibility of the causative organism, the patient's age and clinical status, and kidney or liver function.

IV doses must be appropriately diluted and infused over the recommended period. Patients with severe renal or hepatic impairment may require dosage modification and additional monitoring.

These doses are provided as general clinical reference information. The exact regimen must follow the locally approved product information and the prescribing healthcare professional's instructions.

Can Lincomycin HCl Injection be used in patients with kidney or liver impairment?

Lincomycin is eliminated more slowly in patients with severe renal or hepatic impairment. Dose adjustment, clinical monitoring, and in some cases monitoring of serum lincomycin concentrations may be necessary, particularly during high-dose therapy.

Can Lincomycin HCl Injection be used during pregnancy or breastfeeding?

Use during pregnancy should be assessed by a healthcare professional and limited to situations in which treatment is clearly needed according to the approved local prescribing information.

Lincomycin has been reported in human breast milk. A healthcare professional should weigh the importance of treatment to the mother against the potential risk to the nursing infant when deciding whether breastfeeding or the medicine should be discontinued.

Can Lincomycin HCl Injection be used to treat meningitis?

Lincomycin is not considered suitable for the treatment of meningitis because concentrations achieved in cerebrospinal fluid may be inadequate.

Can Lincomycin HCl Injection interact with other medicines?

Lincomycin has neuromuscular blocking properties and may enhance the effects of other neuromuscular blocking agents. Patients should inform the prescribing healthcare professional about all prescription medicines, over-the-counter medicines, and supplements they are taking before treatment.

Refer to a doctor or pharmacist for guidelines on dosage, administration, interactions, and treatment duration.

As with all pharmaceuticals, unwanted effects can occur from the use of Lincomycin HCl Injection.

For a comprehensive understanding of all potential side effects, consult a medical professional and the locally approved prescribing information.

Seek medical attention promptly if severe diarrhea, difficulty breathing, facial or throat swelling, a severe skin reaction, jaundice, unusual bleeding or bruising, or other serious symptoms develop.

Lincomycin has been associated with severe [Clostridioides difficile-associated diarrhea](https://www.cdc.gov/c-diff/hcp/clinical-overview/) and colitis. Significant, persistent, watery, or bloody diarrhea occurring during treatment or in the weeks after antibiotic use requires prompt medical assessment.

For intravenous use, lincomycin must be appropriately diluted and infused at the recommended rate. It should not be administered as a rapid intravenous bolus because severe cardiopulmonary reactions have been reported when excessive concentrations or infusion rates were used.

During prolonged therapy, periodic monitoring of liver function, kidney function, and blood counts may be required. Patients with severe renal or hepatic impairment may require dosage adjustment and closer monitoring.

Lincomycin should be used only for infections proven or strongly suspected to be caused by susceptible bacteria. Appropriate antibiotic selection, culture-guided treatment where available, and completion of the prescribed course help reduce unnecessary antibiotic exposure and the development of [antimicrobial resistance](https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance).

Before treatment, consult your doctor regarding any medications you are taking to address potential drug interactions.

This medication may not be suitable for people with certain conditions. Treatment decisions should follow the locally approved prescribing information and the judgment of a qualified healthcare professional.